Spyre Therapeutics (SYRE) Free Cash Flow (2015 - 2026)

Spyre Therapeutics has reported Free Cash Flow for 12 years, with the latest figure at -$57.4 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 39.95% year-over-year to -$57.4 million; the trailing twelve-month figure through Mar 2026 stood at -$185.6 million (down 9.28% YoY), and the FY2025 full-year result was -$169.3 million, down 7.52% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$57.4 million, down from -$44.6 million in the prior quarter.
• The five-year high for Free Cash Flow was -$15.1 million in Q3 2022, with the low at -$62.2 million in Q2 2024.
• Historically, Free Cash Flow has averaged -$33.1 million across 5 years, with a median of -$31.0 million in 2023.
• Annual changes were most pronounced in 2022 — Free Cash Flow plunged 923.95% — and 2023, when it jumped 32.95%.
• Spyre Therapeutics' Free Cash Flow stood at -$18.1 million in 2022, then slumped by 71.09% to -$31.0 million in 2023, then decreased by 19.86% to -$37.2 million in 2024, then retreated by 19.84% to -$44.6 million in 2025, then declined by 28.7% to -$57.4 million in 2026.
• The last three Free Cash Flow figures came in at -$57.4 million (Q1 2026), -$44.6 million (Q4 2025), and -$37.1 million (Q3 2025), per Business Quant data.